MX2022008096A - Composiciones que comprenden aminoacidos para su uso en la prevencion y tratamiento de los efectos secundarios de la quimioterapia. - Google Patents

Composiciones que comprenden aminoacidos para su uso en la prevencion y tratamiento de los efectos secundarios de la quimioterapia.

Info

Publication number
MX2022008096A
MX2022008096A MX2022008096A MX2022008096A MX2022008096A MX 2022008096 A MX2022008096 A MX 2022008096A MX 2022008096 A MX2022008096 A MX 2022008096A MX 2022008096 A MX2022008096 A MX 2022008096A MX 2022008096 A MX2022008096 A MX 2022008096A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
amino acids
inhibitors
compositions
Prior art date
Application number
MX2022008096A
Other languages
English (en)
Inventor
Paolo Luca Maria Giorgetti
Original Assignee
Professional Dietetics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics Spa filed Critical Professional Dietetics Spa
Publication of MX2022008096A publication Critical patent/MX2022008096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición para su uso en la prevención y/o en el tratamiento de la cardiotoxicidad inducida por al menos un agente quimioterapéutico en un sujeto sometido a quimioterapia, la composición comprende un agente activo, dicho agente activo contiene los aminoácidos leucina, isoleucina, valina, treonina, lisina y ácido cítrico, ácido succínico, ácido málico. Dicho agente quimioterapéutico puede ser seleccionado en el grupo que consiste en antraciclinas, inhibidores de HR2/ErbB2, inhibidores de tirosina-cinasa, inhibidores del factor de crecimiento endotelial vascular, inhibidores del punto de control inmunológico.
MX2022008096A 2020-01-13 2020-12-21 Composiciones que comprenden aminoacidos para su uso en la prevencion y tratamiento de los efectos secundarios de la quimioterapia. MX2022008096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102020000000442A IT202000000442A1 (it) 2020-01-13 2020-01-13 Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
PCT/IB2020/062291 WO2021144639A1 (en) 2020-01-13 2020-12-21 Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects

Publications (1)

Publication Number Publication Date
MX2022008096A true MX2022008096A (es) 2022-07-27

Family

ID=70009337

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008096A MX2022008096A (es) 2020-01-13 2020-12-21 Composiciones que comprenden aminoacidos para su uso en la prevencion y tratamiento de los efectos secundarios de la quimioterapia.

Country Status (15)

Country Link
US (1) US12472159B2 (es)
EP (1) EP3848025B9 (es)
JP (1) JP2023509627A (es)
KR (1) KR20220128629A (es)
CN (1) CN114980878A (es)
AU (1) AU2020423611B2 (es)
BR (1) BR112022013418A2 (es)
CA (1) CA3166643A1 (es)
CL (1) CL2022001780A1 (es)
ES (1) ES2954594T3 (es)
IT (1) IT202000000442A1 (es)
MX (1) MX2022008096A (es)
PL (1) PL3848025T3 (es)
WO (1) WO2021144639A1 (es)
ZA (1) ZA202207728B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
CN113425707B (zh) * 2021-07-30 2022-12-30 青岛大学附属医院 壬二酸预防蒽环类抗肿瘤药物心肌毒性的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPH0873351A (ja) 1994-06-30 1996-03-19 Ajinomoto Co Inc 炎症性腸疾患用栄養組成物
EP1032403B1 (en) 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
ITTO20010804A1 (it) 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
US6620850B2 (en) 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
JPWO2006046746A1 (ja) 2004-10-26 2008-05-22 味の素株式会社 内臓痛予防・治療剤
WO2007049818A1 (ja) 2005-10-27 2007-05-03 Ajinomoto Co., Inc. 抗脂肪肝、抗肥満及び抗高脂血症用組成物
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
JP2007161642A (ja) 2005-12-14 2007-06-28 Kyowa Hakko Kogyo Co Ltd アルコール性肝障害抑制剤
KR102069790B1 (ko) 2010-09-24 2020-01-23 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
EP2676664B1 (en) 2011-02-17 2017-06-21 EA Pharma Co., Ltd. Potentiator of antitumor activity of chemotherapeutic agent
WO2012147901A1 (ja) * 2011-04-28 2012-11-01 味の素株式会社 抗癌剤副作用改善用組成物
US20130084378A1 (en) 2011-09-30 2013-04-04 Daesang Corporation Amino acid seasoning compositions comprising l-glutamic acid and l-lysine
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US20160038565A1 (en) * 2012-06-15 2016-02-11 Gencia Corporation Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy
CN102772407B (zh) 2012-08-01 2014-09-17 岳茂兴 一种促进神经损伤修复的药物组合物及其应用
US20140243400A1 (en) 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
US9597367B2 (en) 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
CN106999521A (zh) 2014-12-09 2017-08-01 株式会社日本自然发酵 老化抑制剂
CA2973433A1 (en) 2015-01-23 2016-07-28 Nestec S.A. Nutritional composition useful in the treatment of ibd patients
CN105982914A (zh) 2015-01-30 2016-10-05 刘力 复方氨基酸注射液18aa-i的新药物组合物和用途
MX357998B (es) 2015-03-20 2018-07-11 Antonio Hernandez Miramontes Jorge Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
WO2016179657A1 (en) 2015-05-11 2016-11-17 Newcastle Innovation Limited Amino acid supplementation
ES2779749T3 (es) 2015-05-14 2020-08-19 Professional Dietetics Int Srl Composiciones que comprenden aminoácidos para uso en el tratamiento de mucositis en pacientes con neoplasia que están sometidos a radioterapia y/o quimioterapia
US20180221457A1 (en) 2015-07-31 2018-08-09 Val-Chum, Limited Partnership Glycerol-3-phosphate phosphatase activators
KR20180084069A (ko) * 2015-11-27 2018-07-24 더블굳 아브 대사증후군 치료용 식품 보충제 및 조성물
EP3615018A1 (en) 2017-04-28 2020-03-04 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
JP7352901B2 (ja) 2017-10-02 2023-09-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 腫瘍成長を阻害するための材料および方法
WO2019165321A1 (en) 2018-02-23 2019-08-29 Ava Food Labs, Inc. Moscato wine replicas produced from individual components
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000018913A1 (it) 2020-07-31 2022-01-31 Vetagro Int S R L Composizioni comprendenti timolo e amminoacidi per uso nel trattamento di disturbi intestinali infiammatori o funzionali mediante modulazione del sistema endocannabinoide
WO2022266480A1 (en) 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof

Also Published As

Publication number Publication date
US12472159B2 (en) 2025-11-18
KR20220128629A (ko) 2022-09-21
ES2954594T3 (es) 2023-11-23
EP3848025C0 (en) 2023-06-07
CN114980878A (zh) 2022-08-30
IT202000000442A1 (it) 2021-07-13
JP2023509627A (ja) 2023-03-09
AU2020423611B2 (en) 2025-12-11
BR112022013418A2 (pt) 2022-09-20
EP3848025B9 (en) 2023-08-16
PL3848025T3 (pl) 2023-10-30
EP3848025B1 (en) 2023-06-07
CL2022001780A1 (es) 2023-02-03
EP3848025A1 (en) 2021-07-14
WO2021144639A1 (en) 2021-07-22
CA3166643A1 (en) 2021-07-22
AU2020423611A1 (en) 2022-07-21
ZA202207728B (en) 2023-04-26
US20230067642A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2022008096A (es) Composiciones que comprenden aminoacidos para su uso en la prevencion y tratamiento de los efectos secundarios de la quimioterapia.
PH12020500190A1 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases
PH12020552254A1 (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
MX2022008095A (es) Composiciones que comprenden aminoacidos para la prevencion y/o el tratamiento del cancer.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
IN2014KN01713A (es)
IN2014KN01714A (es)
IN2014KN01716A (es)
MY200739A (en) Compositions comprising amino acids for use in the treatment of obesity
WO2019085982A8 (zh) 一种抗pd-l1人源化单克隆抗体的药物组合物
PH12021551884A1 (en) Compositions comprising amino acids for use and treatment of central nervous system injuries
MX2010002448A (es) Formulacion liquida del g-csf conjugado.
WO2015138784A3 (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis
MY199203A (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
PH12018501060A1 (en) Composition for preventing or treating hair loss comprising chemokine (c-x-c motif) ligand 1 (cxcl1) protein
NZ761076B2 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
NZ761073B2 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
MX2025010488A (es) Composicion farmaceutica para tratamiento y/o prevencion del cancer
NZ760312A (en) Use of glutamine synthetase for treating hyperammonemia
TH2001000484A (th) องค์ประกอบซึ่งประกอบรวมด้วยกระอะมิโนสำหรับใช้ในการรักษาโรคที่เกี่ยวข้องกับการทำหน้าที่ผิดปกติของไมโครทอนเดรีย
NZ757874A (en) Stable antibody formulation
MX2019001280A (es) NUEVAS COMPOSICIONES FARMACEUTICAS CON UN PEPTIDO DE FUSION DE LA BETA-DEFENSINA MODIFICADA HßD3-M Y ANTIBIOTICOS COMERCIALES PARA SU USO EN EL TRATAMIENTO DE INFECCIONES CON BACTERIAS PATOGENAS.
WO2019040406A3 (en) Methods of treatments using growth hormone variants and compositions therefor
NZ760312B2 (en) Use of glutamine synthetase for treating hyperammonemia
WO2012067427A3 (ko) Lk8 단백질을 유효성분으로 포함하는 당뇨망막병증 또는 노인성 황반변성의 예방 또는 치료용 약학 조성물